StreetAlpha.app
Home › Stocks › TARS

Tarsus Pharmaceuticals, Inc. (TARS)

Healthcare
$73.01
▼ −6.00%
LAST CLOSE · NOV 20

Tarsus Pharmaceuticals develops and sells eye care treatments, including XDEMVY for an eyelid condition caused by mites. It last closed at $73.01 on Nov 20, down 6.00% on the day. The next earnings report for TARS is expected around Mon, Feb 22, 2027, after the close. For the quarter ended Sep 2026, TARS reported EPS of -$14.40 on revenue of $194.6M, with revenue up 63.9% from a year ago. Over its last 8 reports the stock moved an average of 6.9% the session after earnings. Over the last 12 months TARS insiders bought $0 of stock on the open market and sold $20.8M, according to SEC Form 4 filings.

AI Auto Pilots
Is TARS in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold TARS.

Key Stats

Last 12 months
Results
Revenue
$682.2M
+86.3% vs a year ago
Net income
−$702.2M
−102.9% margin
EPS (diluted)
−$15.86
Free cash flow
$32.4M
4.8% margin
Valuation
Market cap
$3.6B
49.3M shares
P/E
–
No P/E while losing money
Price to sales
5.3
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$136.5M
At Sep 30
Debt
$72.9M
At Sep 30
Shareholder equity
$104.0M
Shares outstanding
49.3M
At Oct 29
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $57.0M$57.0MFY2021FY2022: $25.8M$25.8MFY2022FY2023: $17.4M$17.4MFY2023FY2024: $183.0M$183.0MFY2024FY2025: $451.4M$451.4MFY2025

From TARS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 3). Last 12 months adds up the four latest quarters.

Next report
Feb 22
Estimated date · After the close
Reported EPS
-$14.40
Quarter ended Sep 2026
Year ago EPS
-$0.30
Same quarter last year
Revenue
$194.6M
+63.9% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.59Dec '24Mar 2025: -$0.64Mar '25Jun 2025: -$0.48Jun '25Sep 2025: -$0.30Sep '25Dec 2025: -$0.19Dec '25Mar 2026: -$0.16Mar '26Jun 2026: -$0.43Jun '26Sep 2026: -$14.40Sep '26Latest -$14.40
Revenue by quarter
Dec 2024: $66.4MDec '24Mar 2025: $78.3MMar '25Jun 2025: $102.7MJun '25Sep 2025: $118.7MSep '25Dec 2025: $151.7MDec '25Mar 2026: $162.1MMar '26Jun 2026: $173.9MJun '26Sep 2026: $194.6MSep '26Latest $194.6M
How TARS moved after its last 8 reports
Average move the session after a report ±6.9%
Nov 3, 2026After the close−4.9%
Aug 6, 2026Time not announced+6.6%
May 6, 2026After the close−1.2%
Feb 23, 2026After the close+7.8%
Nov 4, 2025After the close−4.6%
Aug 6, 2025After the close+15.2%
May 1, 2025After the close−5.8%
Feb 25, 2025Time not announced−9.3%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on TARSStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on TARS
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on TARS

Technical Analysis

TARS · as of the Nov 20 close · updated each morning
Moving sideways

The stock is 1% below its 20 day and 1% below its 50 day average. It is 6% above its 200 day average, so the longer trend is still up. Momentum is improving (RSI 48). The nearest support is the Pivot S1 at $71.02, and the nearest resistance the swing high (Oct 22) at $73.11.

Short trendNeutral
Long trendBullish
MomentumImproving
StretchNormal
VolatilityHigh, 5.2%/day
Key levels
$91.5352 week high+25.4%
$76.56Pivot R1+4.9%
$74.56Pivot+2.1%
$74.0950 day average+1.5%
$73.7620 day average+1.0%
$73.11Swing high (Oct 22)+0.1%
$73.01Last close
$71.02Pivot S1−2.7%
$70.85100 day average−3.0%
$69.47Swing low (Aug 27)−4.8%
$68.27200 day average−6.5%
$53.8952 week low−26.2%
Indicators
RSI (14)47.66Middle of its rangeNeutral
MACD1.05Above its signal lineBullish
Stochastic63.7Middle of its rangeNeutral
ADX (14)17.5No clear trend
Williams %R-52.1Oversold below −80, overbought above −20Neutral
CCI (20)19.9Oversold below −100, overbought above 100Neutral
Rate of change+6.4%Change over 10 sessionsBullish
ATR (14)$3.83Typical daily range, 5.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Above
MA 200Above
What happened before, for TARS

What happened before

See how TARS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow TARS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How TARS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for TARSHow many large options trades hit TARS, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

TARS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●142 buying vs 127 selling
  • ▲Held by funds +8.1 pts
  • ●Funds holding -1
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding256257−0.4%
In funds' top 1092+350.0%
Held by funds106.1%97.9%+8.1 pts
New / increased45 / 9737 / 103+1.4%
Reduced / sold out81 / 4684 / 34+7.6%
Put/call ratio0.0212.34−99.8%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See TARS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

TARS Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$20.8M26 sales · 9 insiders
65% of the selling was under pre-arranged trading plans.
2025-12 sold $3.1M2026-01 sold $1.3M2026-03 sold $7.9M2026-06 sold $2.5M2026-09 sold $5.2M2026-11 sold $803KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 13Bobak R. AzamianPresident/CEO and Board ChairSale plan10,000$80.31$803K
Sep 15William J Link PhdDirectorSale plan12,500$78.38$980K
Sep 4Seshadri NeervannanCOOSale plan4,564$85.00$388K
Sep 4Bobak R. AzamianPresident/CEO and Board ChairSale plan10,000$90.56$906K
Sep 4Elizabeth Yeu LinChief Medical OfficerSale plan13,953$87.50$1.2M
Sep 2Bobak R. AzamianPresident/CEO and Board ChairSale plan10,000$80.06$801K
Every insider buy and sale for TARS over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See TARS insider trades →

From SEC Form 4 filings by TARS's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TARS is in one of them and how their past TARS trades turned out.

TARS in the AI portfolios
Loading…

TARS News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered TARS in an article yet. Here's the latest on the wider market.

TARS in the news

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals is a biopharmaceutical company based in Irvine, California, focused on developing and selling treatments for eye care. Its main product, XDEMVY, is an eye solution approved in the United States for Demodex blepharitis, an inflammation of the eyelids caused by mites. The company markets this product to eye care professionals and is developing other treatments, including candidates for ocular rosacea and for preventing Lyme disease.

Headquarters
Irvine, CA